atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack — the drugmaker accused two of the companies of…
Hypertension, or high blood pressure, is known to have a direct impact on heart attack and stroke risk — but a new study has revealed its surprising link to brain health.
In a large, randomized trial, researchers led by First Hospital…
Attendees
Sponsors and Exhibitors
AI In Healthcare: A Virtual Course
Contact us